FIELD: biotechnology.
SUBSTANCE: group of inventions is described, including a ligand-drug against B7H3 conjugate or its pharmaceutically acceptable salt, a pharmaceutical composition for the treatment of diseases or disorders mediated with B7H3, the use of the above-mentioned ligand-drug conjugate or its pharmaceutically acceptable salt or the pharmaceutical composition in the preparation of drugs for the treatment of B7H3-mediated diseases or disorders, and the use of the above-mentioned ligand-drug conjugate or its pharmaceutically acceptable salt or the pharmaceutical composition in the preparation of drugs for the treatment and/or prevention of cancer mediated with B7H3.
EFFECT: invention expands the arsenal of remedies against B7H3.
17 cl, 13 dwg, 9 tbl, 24 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-BCMA ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND MEDICAL USE THEREOF | 2020 |
|
RU2819660C2 |
| ANTIBODY TO CD3 AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2802272C2 |
| LIGAND-DRUG CONJUGATE OF EXATECAN ANALOGUE, ITS PRODUCTION METHOD AND ITS USE | 2019 |
|
RU2793316C2 |
| ANTIBODY-DRUG CONJUGATE, INTERMEDIATE FOR ITS PRODUCTION, METHOD OF ITS PRODUCTION AND ITS USE | 2020 |
|
RU2800137C1 |
| ANTIBODY AGAINST B7-H3, ITS ANTIGEN-BINDING FRAGMENT AND THEIR MEDICAL USE | 2018 |
|
RU2765306C2 |
| ANTIBODY TO B7-H4, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2792748C2 |
| SCREENING OF ATTACHMENT SITES WITH FIXED POINT IN CYSTEINE-MODIFIED ANTIBODY-TOXIN (TDC) CONJUGATE | 2018 |
|
RU2816510C2 |
| CONJUGATES OF BINDER AND ACTIVE SUBSTANCE (ADC) HAVING ENZYMATICALLY CLEAVABLE GROUPS | 2017 |
|
RU2761390C2 |
| ANTIBODY-DRUG CONJUGATES CONTAINING HERBOXYDIENE-BASED SPLICING MODULATOR, AND METHODS OF USE THEREOF | 2019 |
|
RU2820607C2 |
| ANTIBODY TO PD-L1, ITS ANTIGEN-BINDING FRAGMENT, AND THEIR PHARMACEUTICAL USE | 2019 |
|
RU2778085C2 |
